OraSure Technologies (NASDAQ:OSUR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Friday.
Separately, Evercore ISI upped their price target on OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.67.
Get Our Latest Stock Analysis on OSUR
OraSure Technologies Stock Up 1.5 %
OraSure Technologies (NASDAQ:OSUR – Get Free Report) last posted its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 EPS for the quarter. The business had revenue of $54.34 million for the quarter, compared to the consensus estimate of $53.35 million. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. On average, sell-side analysts anticipate that OraSure Technologies will post -0.11 earnings per share for the current fiscal year.
Institutional Investors Weigh In On OraSure Technologies
Large investors have recently bought and sold shares of the company. Sei Investments Co. increased its holdings in shares of OraSure Technologies by 314.0% during the 1st quarter. Sei Investments Co. now owns 170,748 shares of the medical instruments supplier’s stock valued at $1,050,000 after purchasing an additional 129,509 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of OraSure Technologies by 1,017.1% in the 1st quarter. Russell Investments Group Ltd. now owns 178,372 shares of the medical instruments supplier’s stock valued at $1,097,000 after purchasing an additional 162,404 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in OraSure Technologies by 135.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 492,477 shares of the medical instruments supplier’s stock worth $3,029,000 after purchasing an additional 283,001 shares during the period. Acadian Asset Management LLC lifted its position in shares of OraSure Technologies by 46.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,590,258 shares of the medical instruments supplier’s stock valued at $9,776,000 after buying an additional 503,804 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in OraSure Technologies by 428.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 152,003 shares of the medical instruments supplier’s stock valued at $648,000 after purchasing an additional 123,248 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Further Reading
- Five stocks we like better than OraSure Technologies
- 3 Small Caps With Big Return Potential
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is a SEC Filing?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.